Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Schizophrenia Age: Adult |
Dose: Oral – 2 mg/day Frequency: once daily initially Note: May be increased in increments of 1-2 mg/day at intervals greater than 24 hours. Recommended target dosage: 2-8 mg/day once daily or divided every 12 hours (efficacy follows bell-shaped curve; 4-8 mg/day more effective than 12-16 mg/day). |
|
Indication: Bipolar Mania Age: Adult |
Dose: Oral – 2-3 mg/day Frequency: once daily initially Note: May be increased if necessary in increments of 1 mg/day at intervals of 24 hours to 6 mg/day; dosage recommendations not available for treatment duration greater than 3 weeks. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Schizophrenia Age: <13 years |
Dose: Oral Note: Safety and efficacy not established. |
|
Indication: Schizophrenia Age: >13 years |
Dose: Oral – 0.5 mg/day Note: Initial dose administered in morning or evening. If persistent somnolence occurs, daily dose may be divided every 12 hours. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Tablet – 0.5 mg Frequency: twice daily Note: Initially 0.5 mg twice daily, may increase in steps of 0.5 mg twice daily, up to 1-2 mg twice daily. Dose increments above 1.5 mg twice daily should be made at intervals of at least 1 week. |
Administration
- Can be taken with or without food
- Take at same time daily
Side Effect
- Somnolence (40-45%)
- Insomnia (26-30%)
- Agitation (20-25%)
- Anxiety (10-15%)
- Headache (10-15%)
- Rhinitis (10-15%)
- Fatigue (18-31%)
- Parkinsonism (28-62%)
- Akathisia (5-11%)
- Increased appetite (4-44%)
- Vomiting (10-20%)
- Drooling (Less than 12%)
- Urinary incontinence (5-22%)
- Tremor (11-24%)
- Nasopharyngitis (4-19%)
- Rhinorrhea (4-12%)
- Enuresis (1-16%)
- Constipation (5-10%)
- Dyspepsia (5-10%)
- Nausea (5-10%)
- Abdominal pain (1-5%)
- Aggressive reaction (1-5%)
- Facial edema (Less than 4%)
- QT prolongation (Less than 4%)
- Dizziness (1-5%)
- Extrapyramidal symptoms (EPS, 1-5%)
- Gynecomastia in children (1-5%)
- Rash (1-5%)
- Tachycardia (1-5%)
- Syncope (1-2%)
- Bradycardia (Less than 4%)
- Palpitation (Less than 4%)
- Chest pain (Less than 4%)
- Agitation (Less than 4%)
- Postural dizziness (Less than 4%)
- Pruritus (Less than 4%)
- Acne (1-2%)
- Hyperprolactinemia (Less than 4%)
- Sexual dysfunction (Less than 4%)
- Xerostomia (7-10%)
- Agranulocytosis
- Cholesterol increased
- Delirium
- Ketoacidosis
- Orthostatic hypotension
- Seizures
- Diabetes mellitus
- Hyperthermia
- Hypoglycemia
- Hypothermia
- Myelosuppression
- Neuroleptic malignant syndrome (NMS)
- Priapism
- Prolonged QT interval
- Tardive dyskinesia
- Thrombotic thrombocytopenic purpura (TTP)
- Sleep apnea syndrome
- Neuroleptic malignant syndrome may occur rarely
- seizures
- May cause increased mortality in elderly with dementia-related psychosis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Levodopa, Dopamine Agonists (Bromocriptine, Pergolide, Ropinirole, Pramipexole)
|
May antagonize effects
|
|
Clozapine
|
May increase serum levels of clozapine
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Can cause severe allergic reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
The entire dose pack should be stored in the refrigerator (2°-8°C) and protected from light. Keep out of reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.